health - "cancer"

Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that The New England Journal of medicine published landmark results of a Nexavar study in liver cancer. The data of the Phase III trial showed that Nexavar® (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo.

There's something new under the sun at South Dakota State University: Researchers are working with molecules that protect against skin cancer and may even help undo the sun's damage. Distinguished professor Chandradhar Dwivedi, head of the Pharmaceutical Sciences Department in the College of Pharmacy at SDSU, said the work could be commercialized within 10 years. 'We are looking at a number of molecules that can be used with sunscreen or without sunscreen.